| pubmed-article:21532339 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21532339 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:21532339 | lifeskim:mentions | umls-concept:C0007102 | lld:lifeskim |
| pubmed-article:21532339 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
| pubmed-article:21532339 | lifeskim:mentions | umls-concept:C0039294 | lld:lifeskim |
| pubmed-article:21532339 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:21532339 | lifeskim:mentions | umls-concept:C0520484 | lld:lifeskim |
| pubmed-article:21532339 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:21532339 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21532339 | pubmed:dateCreated | 2011-7-4 | lld:pubmed |
| pubmed-article:21532339 | pubmed:abstractText | Gallotannin (GT), the polyphenolic hydrolyzable tannin, exhibits anti-inflammatory and anticancer activities through mechanisms that are not fully understood. Several effects modulated by GT have been shown to be linked to interference with inflammatory mediators. Considering the central role of nuclear factor kappa B (NF-?B) in inflammation and cancer, we investigated the effect of GT on NF-?B signaling in HT-29 and HCT-116 human colon cancer cells. DNA binding assays revealed significant suppression of tumor necrosis factor (TNF-?)-induced NF?B activation which correlated with the inhibition of I?B? phosphorylation and degradation. Sequentially, p65 nuclear translocation and DNA binding were inhibited. GT also down-regulated the expression of NF?B-regulated inflammatory cytokines (IL-8, TNF-?, IL-1?) and caused cell cycle arrest and accumulation of cells in pre-G 1 phase. In vivo, GT (25 mg/kg body weight) injected intraperitoneally (i.p.) prior to or after tumor inoculation significantly decreased the volume of human colon cancer xenografts in NOD/SCID mice. GT-treated xenografts showed significantly lower microvessel density (CD31) as well as lower mRNA expression levels of IL-6, TNF-? and IL-1? and of the proliferation (Ki-67) and angiogenesis (VEGFA) proteins, which may explain GTs in vivo anti-tumorigenic effects. Overall, our results indicate that the anti-inflammatory and antitumor activities of GT may be mediated in part through the suppression of NF-?B activation. | lld:pubmed |
| pubmed-article:21532339 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21532339 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21532339 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21532339 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21532339 | pubmed:issn | 1555-8576 | lld:pubmed |
| pubmed-article:21532339 | pubmed:author | pubmed-author:Schneider-Sto... | lld:pubmed |
| pubmed-article:21532339 | pubmed:author | pubmed-author:BazarbachiAli... | lld:pubmed |
| pubmed-article:21532339 | pubmed:author | pubmed-author:Gali-Muhtasib... | lld:pubmed |
| pubmed-article:21532339 | pubmed:author | pubmed-author:Abou... | lld:pubmed |
| pubmed-article:21532339 | pubmed:author | pubmed-author:El-HajjHibaH | lld:pubmed |
| pubmed-article:21532339 | pubmed:author | pubmed-author:Al-HalabiRach... | lld:pubmed |
| pubmed-article:21532339 | pubmed:author | pubmed-author:Bou... | lld:pubmed |
| pubmed-article:21532339 | pubmed:author | pubmed-author:ZahrHindH | lld:pubmed |
| pubmed-article:21532339 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21532339 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21532339 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:21532339 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21532339 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21532339 | pubmed:pagination | 59-68 | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:meshHeading | pubmed-meshheading:21532339... | lld:pubmed |
| pubmed-article:21532339 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21532339 | pubmed:articleTitle | Gallotannin inhibits NF?B signaling and growth of human colon cancer xenografts. | lld:pubmed |
| pubmed-article:21532339 | pubmed:affiliation | American University of Beirut, Lebanon. | lld:pubmed |
| pubmed-article:21532339 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21532339 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
